Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review

Saudi Pharmaceutical Journal

Volumn 24, Issue 4, 2016, Pages 458-472

  Nidhi, ^a   Rashid, Muzamil ^a   Kaur, Veerpal ^a   Hallan, Supandeep Singh ^a   Sharma, Saurabh ^a   Mishra, Neeraj ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Colon; Inflammatory bowel disease; Multiparticulate carrier; pH sensitive polymer; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BALSALAZIDE; CELLULOSE; CHITOSAN; CIPROFLOXACIN; COPOLYMER; DEOXYGLUCOSE; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; DRUG CARRIER; EUDRAGIT; GUAR GUM; HYDROXYPROPYLMETHYLCELLULOSE; INFLIXIMAB; MESALAZINE; METHACRYLIC ACID; METHOTREXATE; METRONIDAZOLE; MICROPARTICLE CARRIER; MICROSPHERE; NANOCARRIER; NANOSPHERE; OLSALAZINE; POLYMER; PREDNISONE; PRODRUG; SALAZOSULFAPYRIDINE; SOLVENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COLON; CONTROLLED DRUG RELEASE; DIFFUSION; DOUBLE EMULSIFICATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG SAFETY; ELIXIR; EMULSION; EVAPORATION; GELATION; HUMAN; INTERFACIAL POLYMERIZATION; PARTICLE SIZE; PH; POLYMERIZATION; PROCESSING; REVIEW; SINGLE EMULSION TECHNIQUE; SOLVENT EVAPORATION; SPRAY DRYING; SUSTAINED DRUG RELEASE; TABLET FORMULATION; ULCERATIVE COLITIS;

EID: 84999041260     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2014.10.001     Document Type: Review

References (96)

1. Alvarez-Fuentes, J., Fernández-Arévalo, M., González-Rodríguez, M., Cirri, M., Mura, P., Development of enteric-coated timed-release matrix tablets for colon targeting. J. Drug Target. 12:9–10 (2004), 607–612.
2. Ardizzone, S., Porro, G.B., Inflammatory bowel disease: new insights into pathogenesis and treatment. J. Intern. Med. 252:6 (2002), 475–496.
3. Ashford, M., Fell, J.T., Attwood, D., Sharma, H., Woodhead, P.J., An in vivo investigation into the suitability of pH dependent polymers for colonic targeting. Int. J. Pharm. 95:1 (1993), 193–199.
4. Atyabi, F., Vahabzadeh, R., Dinarvand, R., Preparation of ethylcellulose coated gelatin microspheres as a multiparticulate colonic delivery system for 5-aminosalicilic acid. Iran. J. Pharm. Res., 2010, 81–86.
5. Baron, J., Connell, A., Lennard-Jones, J., Avery Jones, F., Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 279:7239 (1962), 1094–1096.
6. Bhat, Subramanya K., Keshavayya, J., Kulkarni, Venkatrao H., Venugoapala Reddy, K.R., Kulkarni, Anandrao R., Kulkarni, Preeti V., Preparation characterization and in-vitro release studies of enteric coated gelatin capsules containing guar gum microspheres for targeted delivery of 5-fluorouracil to colon. Der Pharma Chem. 5:3 (2013), 221–231.
7. Botoman, V.A., Bonner, G.F., Botoman, D.A., Management of inflammatory bowel disease. Am. Fam. Physician 57:1 (1998), 57–68 71-2.
8. Buchman, A.L., Side effects of corticosteroid therapy. J. Clin. Gastroenterol. 33:4 (2001), 289–294.
9. Carter, M.J., Lobo, A.J., Travis, S.P., Guidelines for the management of inflammatory bowel disease in adults. Gut 53:Suppl. 5 (2004), v1–v16.
10. Chandra, Dinesh, Yadav, Indranil Kumar, Singh, Hari Pratap, Jain, D.A., Design and development of satranidazole microspheres for colon targeted drug delivery. Int. J. Pharm. Chem. Sci., 1(3), 2012.
11. Chawla, Anuj, Sharma, Pooja, Pawar, Pravin, Eudragit S-100 coated sodium alginate microspheres of naproxen sodium: formulation, optimization and in vitro evaluation. Acta Pharm. 62 (2012), 529–545.
12. Chourasia, M., Jain, S.K., Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 2003:6 (2003), 33–66.
13. Cole, E.T., Scott, R.A., Connor, A.L., Wilding, I.R., Petereit, H.-U., Schminke, C., et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231:1 (2002), 83–95.
14. Collnot, E.-M., Ali, H., Lehr, C.-M., Nano-and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J. Control. Release 161:2 (2012), 235–246.
15. Coppi, G., Iannuccelli, V., Leo, E., Bernabei, M.T., Cameroni, R., Chitosan–alginate microparticles as a protein carrier. Drug Dev. Ind. Pharm. 27:5 (2001), 393–400.
16. Coppi, G., Iannuccelli, V., Bernabei, M., Cameroni, R., Alginate microparticles for enzyme peroral administration. Int. J. Pharm. 242:1 (2002), 263–266.
17. Cortesi, Rita, Ravani, Laura, Menegatti, Enea, Esposito, Elisabetta, Ronconi, F., Eudragit® microparticles for the release of budesonide: a comparative study. Indian J. Pharm. Sci. 74:5 (2012), 415–421.
18. Cosnes, J., Gower-Rousseau, C., Seksik, P., Cortot, A., Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140:6 (2011), 1785–1794.
19. Dashora, A., Jain, C.P., Development and characterization of pectin-prednisolone microspheres for colon targeted delivery. Int. J. ChemTech Res. 1:3 (2009), 51–757.
20. Egan, L.J., Mays, D.C., Huntoon, C.J., Bell, M.P., Pike, M.G., Sandborn, W.J., et al. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J. Biol. Chem. 274:37 (1999), 26448–26453.
21. Eisen, G.M., Sandler, R.S., Update on the epidemiology of IBD. Prog. Inflamm. Bowel Dis. 15 (1994), 1–8.
22. El-Gibaly, I., Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int. J. Pharm. 232:1–2 (2002), 199–211.
23. Foong, K.S., Patel, R., Forbes, A., Day, R.M., Anti-tumor necrosis factor-alphaloaded Microspheres as a prospective novel treatment for Crohn's disease fistulae. Tissue Eng. Part C Methods 16:16 (2010), 855–864.
24. Ford, A.C., Bernstein, C.N., Khan, K.J., Abreu, M.T., Marshall, J.K., Talley, N.J., et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 106:4 (2011), 590–599.
25. Friend, D.R., New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. 57:2 (2005), 247–265.
26. Fukui, E., Miyamura, N., Uemura, K., Kobayashi, M., Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int. J. Pharm. 204:1 (2000), 7–15.
27. Fuss, I.J., Heller, F., Boirivant, M., Leon, F., Yoshida, M., Fichtner-Feigl, S., et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113:10 (2004), 1490–1497.
28. Gawde, Preeti, Agrawal, Shikha, Jain, Prabhat, Development of mucoadhesive microsphere for colon delivery. Int. J. Pharm. Biol. Arch. 3:3 (2012), 440–442.
29. Ghandehari, H., Kopeckova, P., Kopecek, J., There are various methods for the preparation of nanoparticles which includes ionic gelation method, complex coacervation, emulsion cross linking and spray drying. Biomaterials 18 (1997), 861–872.
30. Gilhotra, Ritu Mehra, Bhardwaj, Vishv Priya, Mishra, D.N., A comparative review of recently developed particulate drug carrier systems. Taxonomy upgrade extras. Target. Drug Deliv. Syst., 7(3), 2009.
31. Harel, E., Rubinstein, A., Nissan, A., Khazanov, E., Nadler Milbauer, M., Barenholz, Y., Tirosh, B., Enhanced transferrin receptor expression by proinflammatory cytokines in enterocytes as a means for local delivery of drugs to inflamed gut mucosa. PLoS One, 6, 2011, e24202.
32. Hashem, Fahima M., Shaker, Dalia S., Nasr, Mohamed, Ragaey, Reem, In vitro and in vivo evaluation of combined time and pH dependent oral colon targeted prednisolone microspheres. Br. J. Pharm. Res. 3:3 (2013), 20–434.
33. Hinton, J., Lennard-Jones, J., Young, A., A new method for studying gut transit times using radioopaque markers. Gut 10:10 (1969), 842–847.
34. Isaacs, K.L., Lewis, J.D., Sandborn, W.J., Sands, B.E., Targan, S.R., State of the art: IBD therapy and clinical trials in IBD. Inflamm. Bowel Dis. 11:S1 (2005), S3–S12.
35. Jain, Sunil K., Rai, Gopal, Saraf, D.K., Agrawal, G.P., Albendazole microspheres for colonic delivery. Pharm. Technol. 28:12 (2004), 66–71.
36. Jeevana, B., Sunitha, J.G., Development and evaluation of gelatin microspheres of tramadol hydrochloride. J. Young Pharm. 1:1 (2009), 24–27.
37. Jeong, Y.-I., Ohno, T., Hu, Z., Yoshikawa, Y., Shibata, N., Nagata, S., et al. Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method. J. Control. Release 71:2 (2001), 175–182.
38. Kakar, S., Batra, D., Singh, R., Nautiyal, U., Magnetic microspheres as magical novel drug delivery system: a review. J. Acute Dis. 2:1 (2012), 1–12.
39. Kawashima, Y., Yamamoto, H., Takeuchi, H., Fujioka, S., Hino, T., Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Cont. Rel. 62 (1999), 279–287.
40. Keerthi, T.S., Vinupama, S., Kamatha, Shwetha S., Singh, Prashanth, Senthil Kumar, S.K. Biodecomposable polymeric microspheres: review. Int. Bull. Drug Res. 1(2), 81.
41. Kim, K.K., Pack, D.W., Microspheres for Drug Delivery. BioMEMS and Biomedical Nanotechnology. 2006, Springer pp. 19–50.
42. Lamprecht, A., Schäfer, U., Lehr, C.-M., Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 18:6 (2001), 788–793.
43. Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Maincent, P., et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299:2 (2001), 75–81.
44. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y., A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J. Control. Release 104:2 (2005), 337–346.
45. Lautenschläger, C., Schmidt, C., Fischer, D., Stallmach, A., Drug delivery strategies in the therapy of inflammatory bowel disease. Adv. Drug Deliv. Rev., 2013.
46. Lautenschläger, C., Schmidt, C., Lehr, C.-M., Fischer, D., Stallmach, A., PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur. J. Pharm. Biopharm. 85:3 (2013), 578–586.
47. Lee, W.W., Wilson, C.G., Mukherji, G., Time-dependent Systems for Colonic Delivery. 2003, Marcel Dekker, New York.
48. Lee, J.K., Tang, D.H., Mollon, L., Armstrong, E.P., Cost-effectiveness of biological agents used in ulcerative colitis. Best Pract. Res. Clin. Gastroenterol. 27:6 (2013), 949–960.
49. Liang, D., Ulcerative colitis: diagnosis and management. Hosp. Physician, 2002, 53.
50. Mahajan, N.M., Sakarkar, D.M., Manmode, A.S., Preparation and characterization of meselamine loaded PLGA nanoparticles. Int. J. Pharm. Pharm. Sci., 3(4), 2011.
51. Mahkam, Mehrdad, Vakhshouri, Laleh, Colon-specific drug delivery behavior of pH-responsive PMAA/perlite composite. Int. J. Mol. Sci. 11:4 (2010), 1546–1556.
52. Makhlof, A., Tozuka, Y., Takeuchi, H., pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur. J. Pharm. Biopharm. 72:1 (2009), 1–8.
53. Mateović-Rojnik, Tatjana, Frlan, Rok, Bogataj, Marija, Bukovec, Peter, Mrhar, Aleš, Effect of preparation temperature in solvent evaporation process on Eudragit RS microsphere properties. Chem. Pharm. Bull. 53:1 (2005), 143–146.
54. Mathew Sam, T., Devi Gayathri, S., Prasanth, V.V., Vinod, B., NSAIDs as microspheres. Int. J. Pharmacol., 6(1), 2008.
55. Meier, J., Sturm, A., Current treatment of ulcerative colitis. World J. Gastroenterol. 17:27 (2011), 3204–3212.
56. Meissner, Y., Ubrich, N., El Ghazouani, F., Maincent, P., Lamprecht, A., Low molecular weight heparin loaded pH-sensitive microparticles. Int. J. Pharm. 335:1–2 (2007), 147–153.
57. Moller, D.R., Wysocka, M., Greenlee, B.M., Ma, X., Wahl, L., Flockhart, D.A., et al. Inhibition of IL-12 production by thalidomide. J. Immunol. 159:10 (1997), 5157–5161.
58. Molodecky, N.A., Kaplan, G.G., Environmental risk factors for inflammatory bowel disease. Gastroenterol. Hepatol., 6(5), 2010, 339.
59. Molodecky, N.A., Soon, I.S., Rabi, D.M., Ghali, W.A., Ferris, M., Chernoff, G., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:1 (2012), 46–54.
60. Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A., Kaplan, G., Thalidomide exerts its inhibitory action on TNF-α by enhancing m RNA degradation. J. Exp. Med. 177:6 (1993), 1675–1680.
61. Nakase, Hiroshi, Okazaki, Kazuichi, Tabata, Yasuhiko, Uose, Suguru, Ohana, Masaya, Uchida, Kazushige, Matsushima, Yumi, Kawanami, Chiharu, Oshima, Chikashi, Ikada, Yoshito, Chiba, Tsutomu, Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther. 292 (2000), 5–21.
62. Navaneethan, U., Jegadeesan, R., Gutierrez, N.G., Venkatesh, P.G., Hammel, J.P., Shen, B., et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J. Crohns Colitis 7:12 (2013), e684–e691.
63. Neurath, M.F., Travis, S.P., Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61:11 (2012), 1619–1635.
64. Newton, A.M.J., Prabakaran, L., Jayaveera, K., Pectin-HPMC E15LV Vs pH sensitive polymer coating films for delayed drug delivery to colon: a comparison of two dissolution models to assess colonic targeting performance in-vitro. Int. J. Appl. Res. Nat. Prod. 5:3 (2012), 1–16.
65. Oosegi, T., Onishi, H., Machida, Y., Gastrointestinal distribution and absorption behavior of Eudragit-coated chitosan–prednisolone conjugate microspheres in rats with TNBS-induced colitis. Int. J. Pharm. 348:1 (2008), 80–88.
66. Papadakis, K.A., Shaye, O.A., Vasiliauskas, E.A., Ippoliti, A., Dubinsky, M.C., Birt, J., et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol. 100:1 (2005), 75–79.
67. Patel, M., Shah, T., Amin, A., Therapeutic opportunities in colon-specific drug-delivery systems. Crit. Rev. Ther. Drug Carrier Syst., 24(2), 2007.
68. Philip, A.K., Philip, B., Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med. J., 25(2), 2010, 79.
69. Raj, Behin Sundara, Shanthi, Nair, Rajesh Sreedharan, Samraj, Punitha Isaac, Vidya, Formulation and evaluation of coated microspheres for colon targeting. J. Appl. Pharm. Sci. 3:8 (2013), 68–S74.
70. Ramana, G., Krishna, Chaitanya A., Preparation and in-vitro characterization of ethyl cellulose coated pectin alginate microspheres of 5-fluorouracil for colon targeting. J Appl. Pharm. Sci. 1:08 (2011), 70–76.
71. Ransford, R., Langman, M., Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51:4 (2002), 536–539.
72. Rasool, Fatima, Ahmad, Mahmood, Murtaza, Ghulam, Khan, Haji M.S., Khan, Shujaat Ali, Eudragitæ fs based colonic microparticles of metoprolol tartrate. Acta Pol. Pharm. 69:2 (2012), 347–353.
73. Riley, S., Mani, V., Goodman, M., Herd, M., Dutt, S., Turnberg, L., Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 29:5 (1988), 669–674.
74. Rodrı́guez, M., Vila-Jato, J.L., Torres, D., Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J. Control. Release 55:1 (1998), 7–77.
75. Rogler, Gerhard, Chronic ulcerative colitis and colorectal cancer. Cancer Lett. 345:2 (2014), 235–241.
76. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353:23 (2005), 2462–2476.
77. Saboktakin, M.R., Tabatabaie, R.M., Maharramov, A., Ramazanov, M.A., Synthesis and in vitro evaluation of carboxymethyl starch–chitosan nanoparticles as drug delivery system to the colon. Int. J. Biol. Macromol. 48:3 (2011), 381–385.
78. Sandborn, W.J., Hanauer, S.B., Katz, S., Safdi, M., Wolf, D.G., Baerg, R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:5 (2001), 1088–1094.
79. Sareen, R., Jain, N., Rajkumari, A., Dhar, K.L., pH triggered delivery of curcumin from Eudragit-coated chitosan microspheres for inflammatory bowel disease: characterization and pharmacodynamic evaluation. Drug Deliv., 2014 (in Press).
80. Scheline, R.R., Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev., 25(4), 1973, 451.
81. Schroeder, K.W., Tremaine, W.J., Ilstrup, D.M., Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317:26 (1987), 625–629.
82. Siegel, S.A., Shealy, D.J., Nakada, M.T., Le, J., Woulfe, D.S., Probert, L., et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7:1 (1995), 15–25.
83. Singh, B.M., Modified-release solid formulations for colonic delivery. Recent Pat. Drug Delivery Formulation 1 (2007), 53–63.
84. Sowmya, Cherukuri, Reddy, Chappidi Suryaprakash, Vishnu Priya, Neelaboina, Sandhya, Reddipalli, Komaragiri, Keerthi, Colon specific drug delivery systems: a review on pharmaceutical approaches with current trends. Int. Res. J. Pharm., 3(7), 2012, 45.
85. Stein, J., Ries, J., Barrett, K.E., Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am. J. Physiol. Gastrointest. Liver Physiol. 274:1 (1998), G203–G209.
86. Strober, W., Fuss, I., Mannon, P., The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117:3 (2007), 514–521.
87. Takada, S., Uda, Y., Toguchi, H., Ogawa, Y., Application of a spray drying technique in the production of TRH-containing injectable sustained-release microparticles of biodegradable polymers. PD J PhAarm. Sci. Technol. 49:4 (1995), 180–184.
88. Talaei, F., Atyabi, F., Azhdarzadeh, M., Dinarvand, R., Saadatzadeh, A., Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. Eur. J. Pharm. Sci. 49:4 (2013), 712–722.
89. Taylor, K.M., Irving, P.M., Optimization of conventional therapy in patients with IBD. Nat. Rev. Gastroenterol. Hepatol. 8:11 (2011), 646–656.
90. Thippeswamy, B.S., Mahendran, S., Biradar, M.I., Raj, P., Srivastava, K., Badami, S., et al. Protective effect of embelin against acetic acid induced ulcerative colitis in rats. Eur. J. Pharmacol. 654:1 (2011), 100–105.
91. Tromm, A., Griga, T., May, B., Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology 46:30 (1998), 3124–3135.
92. Turunen, U.M., Färkkilä, M.A., Hakala, K., Seppälä, K., Sivonen, A., Ögren, M., et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 115:5 (1998), 1072–1078.
93. Varshosaz, Jaleh, Ahmadi, Fatemeh, Emami, Jaber, Tavakoli, Naser, Minaiyan, Mohsen, Mahzouni, Parvin, Dorkoosh, Farid, Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: an in vitro/in vivo evaluation in induced colitis in rat. J. Microencapsul. 28:1 (2011), 2–73.
94. Watnasirichaikul, S., Davies, N.M., Rades, T., et al. Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions. Pharm. Res. 9 (2000), 176684–176689.
95. Whateley, T.L., 1996. Microcapsules: preparation by interfacial polymerization and interfacial complexation and their application. In: Benita, S. (Ed.), Microencapsulation: Methods and Industrial Applications, pp. 349–375.
96. Zhou, S., Fleisher, D., Pao, L., Li, C., Winward, B., Zimmermann, E., Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab. Dispos. 27:4 (1999), 479–485.